| pubmed-article:21648077 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21648077 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:21648077 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:21648077 | lifeskim:mentions | umls-concept:C0025663 | lld:lifeskim |
| pubmed-article:21648077 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:21648077 | lifeskim:mentions | umls-concept:C0302908 | lld:lifeskim |
| pubmed-article:21648077 | lifeskim:mentions | umls-concept:C0680730 | lld:lifeskim |
| pubmed-article:21648077 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:21648077 | lifeskim:mentions | umls-concept:C1148554 | lld:lifeskim |
| pubmed-article:21648077 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:21648077 | pubmed:dateCreated | 2011-7-13 | lld:pubmed |
| pubmed-article:21648077 | pubmed:abstractText | The non-imidazole H3 receptor antagonist UPR1056 was dosed in plasma samples from rats individually administered with a single i.p. dose of 1.25 mg/kg by means of a newly validated HPLC-MS method. UPR1056 was extracted from rat plasma by protein precipitation with acetonitrile and was separated by linear gradient elution, employing water and methanol both additioned with 0.05% trifluoroacetic acid as mobile phases. UPR1056 was detected in MS using an electrospray ion source operating in positive ion mode. Acquisition was performed in single ion monitoring mode at m/z=349.3. The method was validated over the concentration range of 17.43-1743 ng/mL (50-5000 pmol/mL). Within- and between-run precision for the low, mid and high quality controls (QC) levels were 6.75% or less and accuracy ranged from 95.8 to 107.6%. The lower limit of quantification was 17.43 ng/mL. The analysis of the time course of UPR1056 concentrations over the 24-h period revealed a C(max) of 1147 ng/mL after 2 h from peripheral administration of the non-imidazole H(3)-receptor antagonist, with a prolonged elimination half-life of over 9 h. | lld:pubmed |
| pubmed-article:21648077 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21648077 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21648077 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21648077 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21648077 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21648077 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21648077 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21648077 | pubmed:issn | 1615-9314 | lld:pubmed |
| pubmed-article:21648077 | pubmed:author | pubmed-author:MateoM CMC | lld:pubmed |
| pubmed-article:21648077 | pubmed:author | pubmed-author:BarocelliElis... | lld:pubmed |
| pubmed-article:21648077 | pubmed:author | pubmed-author:SilvaClaudiaC | lld:pubmed |
| pubmed-article:21648077 | pubmed:author | pubmed-author:VacondioFeder... | lld:pubmed |
| pubmed-article:21648077 | pubmed:author | pubmed-author:BordiFabrizio... | lld:pubmed |
| pubmed-article:21648077 | pubmed:author | pubmed-author:MoriniGiovann... | lld:pubmed |
| pubmed-article:21648077 | pubmed:author | pubmed-author:FlamminiLisaL | lld:pubmed |
| pubmed-article:21648077 | pubmed:copyrightInfo | Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. | lld:pubmed |
| pubmed-article:21648077 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21648077 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:21648077 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21648077 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21648077 | pubmed:pagination | 1656-63 | lld:pubmed |
| pubmed-article:21648077 | pubmed:meshHeading | pubmed-meshheading:21648077... | lld:pubmed |
| pubmed-article:21648077 | pubmed:meshHeading | pubmed-meshheading:21648077... | lld:pubmed |
| pubmed-article:21648077 | pubmed:meshHeading | pubmed-meshheading:21648077... | lld:pubmed |
| pubmed-article:21648077 | pubmed:meshHeading | pubmed-meshheading:21648077... | lld:pubmed |
| pubmed-article:21648077 | pubmed:meshHeading | pubmed-meshheading:21648077... | lld:pubmed |
| pubmed-article:21648077 | pubmed:meshHeading | pubmed-meshheading:21648077... | lld:pubmed |
| pubmed-article:21648077 | pubmed:meshHeading | pubmed-meshheading:21648077... | lld:pubmed |
| pubmed-article:21648077 | pubmed:meshHeading | pubmed-meshheading:21648077... | lld:pubmed |
| pubmed-article:21648077 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21648077 | pubmed:articleTitle | Liquid chromatography-mass spectrometric method for determination of the non-imidazole H3-receptor antagonist UPR1056 in rat plasma. | lld:pubmed |
| pubmed-article:21648077 | pubmed:affiliation | Dipartimento Farmaceutico, Università degli Studi di Parma, Parma, Italy. federica.vacondio@unipr.it | lld:pubmed |
| pubmed-article:21648077 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21648077 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21648077 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
